Overview#
TD Cowen has revised its price target for Universal Health Services (UHS) from $245 to $230 while maintaining a Buy rating. This change follows the company's first-quarter financial results, which showed both strengths and challenges.
Financial Performance#
In the first quarter, Universal Health Services reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that exceeded expectations by 3%. The company also saw a 1.6% increase in same-store behavioral health adjusted patient days, which fell at the lower end of its guidance range of 2% to 3%. However, there was a noted decline in core growth compared to the previous year.
Price Target Adjustment#
Analyst Ryan Langston explained that the price target adjustment reflects concerns that Universal Health Services may need to achieve higher growth in non-same-day procedures in the latter part of 2026 to meet its full-year guidance. The new price target corresponds to a valuation of 6.9 times the adjusted EBITDA estimate for 2027.
Market Reaction#
Despite these adjustments, Langston believes the market's reaction has been excessive. Currently, UHS shares are trading at $162.54, close to their 52-week low of $152.33, and have dropped 25% year-to-date. However, the company's valuation metrics, including a price-to-earnings (P/E) ratio of 7.09 and a price-to-earnings growth (PEG) ratio of 0.2, suggest that the stock may be undervalued relative to its growth potential. Recent analysis indicates that UHS is among the most undervalued stocks in the market.
Recent Developments#
In addition to the price target change, Universal Health Services reported adjusted earnings of $5.62 per share, surpassing analyst estimates, and revenue of $4.49 billion, which also exceeded forecasts. Despite these positive results, the company faces ongoing pressures from health insurance trends, leading to a recent 6.8% drop in its share price. Investors are closely watching how the company plans to navigate these challenges.